Sugi Predict

Sugi Predict / Compounds / SCHEMBL19971518

SCHEMBL19971518

SCHEMBL19971518

O=C(Cl)c1cn(-c2c(F)cc(F)cc2F)c2nc(Cl)c(F)cc2c1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KEAP1 Q14145 1/20 0.38
▸ NFE2L2 Q16236 1/20 0.38
▸ EPHA2 P29317 1/20 0.38
▸ FLT4 P35916 1/20 0.38
▸ GSK3B P49841 1/20 0.38
▸ RARB P10826 1/20 0.38
▸ TBXAS1 P24557 1/20 0.38
▸ SLC6A3 Q01959 1/20 0.38
▸ KMT2A Q03164 2/20 0.37
▸ CYP2C9 P11712 3/20 0.35
▸ CYP3A4 P08684 2/20 0.35
▸ KDM4E B2RXH2 3/20 0.35
▸ LMNA P02545 2/20 0.35
▸ HPGD P15428 2/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ XBP1 P17861 1/20 0.35
▸ NFKB1 P19838 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ NFKB2 Q00653 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19971429 0.90 KEAP1 (0.48) KEAP1NFE2L2EPHA2FLT4GSK3B
Hydrochloric Acid SCHEMBL28904892 0.89 KEAP1 (0.47) KEAP1NFE2L2EPHA2FLT4GSK3B
SCHEMBL19971400 0.85 EPHA2 (0.45) KEAP1NFE2L2EPHA2FLT4GSK3B
SCHEMBL29980308 0.85 EPHA2 (0.45) KEAP1NFE2L2EPHA2FLT4GSK3B
SCHEMBL18306092 0.84 EPHA2 (0.36) EPHA2FLT4GSK3BRARBTBXAS1
SCHEMBL7009999 0.83 STAT3 (0.48) KMT2AKDM4ELMNAHPGDALDH1A1
SCHEMBL19971503 0.82 EPHA2 (0.44) KEAP1NFE2L2EPHA2FLT4GSK3B
SCHEMBL29980318 0.82 EPHA2 (0.44) KEAP1NFE2L2EPHA2FLT4GSK3B
SCHEMBL19974021 0.82 EPHA2 (0.34) KEAP1NFE2L2EPHA2FLT4GSK3B
SCHEMBL19971439 0.81 PDE4A (0.41) EPHA2FLT4GSK3BRARBTBXAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115554294-A 7-substituted 1-arylnaphthyridine-3-carboxamides and their use 拜耳股份公司 2023-01-03 — — CN disclosed
CN-115477649-A 7-substituted 1-arylnaphthyridine-3-carboxamides and their use 拜耳股份公司 2022-12-16 — — CN disclosed
CN-115429798-A 7-substituted 1-arylnaphthyridine-3-carboxamides and their use 拜耳股份公司 2022-12-06 — — CN disclosed
US-11472803-B2 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof BAYER AKTIENGESELLSCHAFT (DE) 2022-10-18 — — US disclosed
CN-109689656-B 7-substituted 1-arylnaphthyridine-3-carboxamides and their use 拜耳股份公司 2022-10-04 — — CN disclosed
US-20220089591-A1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2022-03-24 — — US disclosed
EP-3512849-B1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDIN-3-CARBOXAMIDES AND THEIR USE BAYER AG (DE) 2021-06-23 — — EP disclosed
EP-3512849-B1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDIN-3-CARBOXAMIDES AND THEIR USE BAYER AG (DE) 2021-06-23 — — EP disclosed
US-10927109-B2 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof BAYER AKTIENGESELLSCHAFT (DE) 2021-02-23 — — US disclosed
US-10927109-B2 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof BAYER AKTIENGESELLSCHAFT (DE) 2021-02-23 — — US disclosed
US-20190263805-A1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2019-08-29 — — US disclosed
US-20190263805-A1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2019-08-29 — — US disclosed
EP-3512849-A1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF Bayer Aktiengesellschaft (DE) 2019-07-24 — — EP disclosed
WO-2018050510-A1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2018-03-22 — — WO disclosed
WO-2018050510-A1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2018-03-22 — — WO disclosed
EP-3296298-A1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDIN-3-CARBOXAMIDES AND THEIR USE Bayer Pharma Aktiengesellschaft (DE) 2018-03-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190263805-A1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF AADAC, GLS, NAT1 KEAP1 2187/4885NFE2L2 571/4885EPHA2 4336/4885
US-20220089591-A1 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF AADAC, GLS, NAT1 KEAP1 2187/4885NFE2L2 571/4885EPHA2 4336/4885
US-10927109-B2 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof AADAC, GLS, NAT1 KEAP1 2187/4885NFE2L2 571/4885EPHA2 4336/4885
US-11472803-B2 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof AADAC, GLS, NAT1 KEAP1 2187/4885NFE2L2 571/4885EPHA2 4336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.